The North America clinical trials market size is set for steady expansion, growing from USD 39.17 billion in 2025 to nearly USD 78.51 billion by 2035, at a CAGR of 7.20%, driven by rising R&D investments, advanced healthcare infrastructure, and increasing demand for innovative therapies.

North America Clinical Trials Market Statical Scope

Due to strong pharmaceutical and biotech investments, advanced research infrastructure, rising chronic disease cases, supportive FDA pathway and increasing adoption of digital decentralized trial technologies.

It is advancing through artificial intelligence -based patient recruitment, cloud clinical platforms, wearable health monitoring devices, remote data capture and central trail models. These technologies improve enrolment speed, data accuracy, regulatory documentation and participant retention. The growing use of predictive analytics and automation is also helping sponsors reduce cost and shorten study timelines, strengthening the reasoning leadership in global clinical research innovations.

North America Clinical Trials Market Share, By Phase, 2025 (%)

• Phase I- The segment accounted for 15.31% of the total market share, due to continuous early-stage drug pipelines, strong biotech funding and specialized centres conducting first in human safety studies efficiently.
• Phase II- The segment accounted for 24.12% of the total market share, due to rising demand for efficacy testing and dose optimization studies and expanding pipelines in oncology and chronic diseases.
• Phase III- The segment dominated the market with a 40.87% share, because large patient involvement, longer study duration, high cost and regulatory approval requirements make these faces the most resource intensive.
• Phase IV- The segment accounted for 19.70% of the total market share, due to growing post-marketing safety monitoring, real world evidence studies and lifecycle management of approved therapies.

North America Clinical Trials Market Share, By Study Design, 2025 (%)

• Interventional Trials- The segment dominated the market with a 65.44% share, because they are essential for testing for new drug advice and therapy before regulatory approval.
• Observational Trials- The segment accounted for 24.21% of the total market share, due to rising demand for real-world evidence. This is monitoring and long-term treatment outcome analysis.
• Expanded Access Trials- The segment accounted for 10.35% of the total market share, due to demand for investigational treatments among patients with serious conditions lacking approved therapeutic options.

North America Clinical Trials Market Share, By Indication, 2025 (%)

• Autoimmune/Inflammation- The segment accounted for 12.48% of the total market share, due to rising prevalence of rheumatoid arthritis, psoriasis IBD and strong demand for biologic.
• Pain Management- The segment accounted for 9.62% of the total market share, due to high chronic pain burden opioid alternatives demand and development of shape non-addictive therapies.
• Oncology- The segment dominated the market with a 30.55% share, due to high cancer incidents, strong R& D funding, precision medicine growth and continuous demand for innovative therapies.

North America Clinical Trials Market Share, By Indication by Study Design, 2025 (%)

• Autoimmune/Inflammation- The segment accounted for 15.62% of the total market share, due to increasing immune disorders biologic drug pipelines and long-term treatment research demand.
• Pain Management- The segment accounted for 9.88% of the total market share, due to rising chronic pain cases and an increased trial for safer non-opioid treatments.
• Oncology- The segment dominated the market with a 29.41% share, due to a high cancer burden, continuous innovation of targeted therapies and strong investment in research.

North America Clinical Trials Market Share, By Service, 2025 (%)

• Protocol Designing- The segment accounted for 10.22% of the total market share, due to rising study complexity, strict regulatory standards and demand for efficient, well-structured trial planning.
• Site Identification- The segment accounted for 11.63% of the total market share, due to growing multicentre studies, faster patient recruitment needs and demand for experience at research locations.
• Patient Recruitment- The segment dominated the market with a 20.34% share, due to enrolment challenges, a diverse population needs rising competition for participants and trial timeline pressures.

North America Clinical Trials Market Share, By Sponsor, 2025 (%)

• Pharmaceutical & Biopharmaceutical Companies- The segment dominated the market with a 70.81% share, due to large R & D budgets, strong drug pipelines and frequent regulatory submissions.
• Medical Device Companies- The segment accounted for 19.12% of the total market share, due to continuous innovation in diagnostics implants variables and strict safety validation requirements.
• Others- The segment accounted for 10.07% of the total market share, due to academic institutes, government agencies and non-profits funding public health and investigator-led studies.

Top Companies in the North America Clinical Trials Market

• IQVIA Inc.
• Parexel International Corporation
• Thermo Fisher Scientific Inc.
• ICON Plc.
• LabCorp
• Syneos Health
• Novotech
• Avance Clinical
• George Clinical
• Veritus Research
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Novo Nordisk A/S
• Pfizer, Inc.
• Actinogen Medical
• Telix Pharmaceuticals
• PYC Therapeutics
• Neuren Pharmaceuticals
• AbbVie
• Merck Sharp & Dohme LLC

Segments Covered in the Report

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Study Design

• Interventional Trials
• Observational Trials
• Expanded Access Trials

By Indication

• Autoimmune/Inflammation
• Pain Management
• Oncology
• CNS Conditions
• Diabetes
• Obesity
• Cardiovascular Diseases

By Study Design

• Autoimmune/Inflammation
• Pain Management
• Oncology
• CNS Conditions
• Diabetes
• Obesity
• Cardiovascular Diseases
• Others

By Service

• Protocol Designing
• Site Identification
• Patient Recruitment
• Laboratory Services
• Analytical Testing Services
• Clinical Trial Data Management Services
• Others

By Sponsor

• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Others